Across TCGA pan-cancer cohorts, HMGN4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated HMGN4 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher HMGN4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HMGN4 expression acts as an unfavorable survival marker.
ESCA are the cancer types where HMGN4 Mutation most reproducibly stratifies survival.